A phase 1/2a multicenter trial to evaluate the safety and immunogenicity of the CD40.Pan.CoV vaccine, adjuvanted or not, as a booster in adult participants

2024-516767-92-01 Protocol ANRS0640s LKV-PAN-01 Human pharmacology (Phase I) - First administration to humans Ongoing, recruitment ended

Start 17 Jun 2025 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 7 sites · Protocol ANRS0640s LKV-PAN-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruitment ended
Participants planned 48
Countries 1
Sites 7

Health Participants

Key facts

Sponsor
ANRS Maladies Infectieuses Emergentes
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Virus Diseases [C02], Diseases [C] - Pathological Conditions, Signs and Symptoms [C23]
Trial duration
17 Jun 2025 → ongoing
Decision date (initial)
2025-04-25
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-516767-92-01
ClinicalTrials.gov
NCT07113106

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Health Participants

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

ANRS Maladies Infectieuses Emergentes

Sponsor organisation
ANRS Maladies Infectieuses Emergentes
Address
101 Rue De Tolbiac
City
Paris
Postcode
75013
Country
France

Scientific contact point

Organisation
ANRS Maladies Infectieuses Emergentes
Contact name
Sabrina ALOUI

Public contact point

Organisation
ANRS Maladies Infectieuses Emergentes
Contact name
Yazdan YAZDANPANAH

Locations

1 EU/EEA country · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruitment ended 48 7
Rest of world 0

Investigational sites

France

7 sites · Ongoing, recruitment ended
University Hospital Of Clermont-Ferrand
CIC1405, 58 Rue Montalembert, 63003, Clermont Ferrand Cedex 1
CHU Henri Mondor
Service d'immunologie clinique et maladies infectieuses, 1 Rue Gustave Eiffel, Maladies Infectieuses & U2TI, Creteil
Centre Hospitalier Universitaire De Caen Normandie
Centre de recherche clinique, Avenue De La Cote De Nacre, Cs 30001, Caen Cedex 9
Centre Hospitalier Universitaire De Nantes
CIC1413, 1 Place Alexis Ricordeau, 44000, Nantes
Centre Hospitalier Universitaire De Lille
CIC 14036 Institut Coeur Poumon, Boulevard Du Professeur Jules Leclercq, 59000, Lille
Hôpital Cochin
CIC 1417 Cochin Pasteur, 27 rue du Fbg St Jacques, 75014, Paris
Hopital Saint Louis
CIC1427, 1 Avenue Claude Vellefaux, 75010, Paris

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2025-06-17 2025-06-18 2026-04-07

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-12-17 France Acceptable
2025-04-22
2025-04-25
2 SUBSTANTIAL MODIFICATION SM-1 2025-10-16 France Acceptable
2025-11-28
2025-12-02
3 SUBSTANTIAL MODIFICATION SM-2 2026-01-29 France Acceptable 2026-03-23